Objective: To explore how potential harms are assessed in trials of behavioral, lifestyle and psychological therapy interventions.
Study Design And Setting: This study was a review of protocols from the National Institute of Health Research Health Technology Assessment and Public Health Research programmes. Protocols were included if the study was a randomized controlled trial and the intervention intended to change lifestyle or behavior to improve health or improve psychological outcomes.
Results: 95 of 151 protocols planned to record adverse events (AEs). Definitions of AEs were often not given and varied widely. Serious AEs were mostly defined using standards originally devised for pharmacological trials. Twenty-two protocols listed expected AEs. Few protocols described assessment of causation between AEs and intervention. Examples of useful AE recording practice were identified.
Conclusion: Monitoring and recording AEs in behavioral intervention trials was variable and frequently based on reporting guidelines for pharmacological trials. This may mean potential harms are being missed. Future trials should consider: 1) Potential harms posed by the intervention 2) How to define serious AEs 3) What are expected AEs. Further research to achieve consensus on AE recording is required, including identification of core adverse outcomes in clinical areas or caused by interventions.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jclinepi.2021.03.002 | DOI Listing |
Braz J Microbiol
January 2025
Virus Bioinformatics Laboratory, Centro de Biotecnologia e Genética, Universidade Estadual de Santa Cruz, Ilhéus, 45662-900, BA, Brazil.
Parasitoid wasps act as natural biological control agents for several harmful insect species. However, there is a lack of information regarding the exogenous RNA viruses that infect parasitoids and may contribute to the success of their parasitism strategies. This study aimed to investigate the presence, abundance, and replication of known exogenous viruses in two parasitoid wasp species and their corresponding preys.
View Article and Find Full Text PDFPhys Chem Chem Phys
January 2025
Departamento de Física Aplicada - Instituto de Ciencia de Materiales, Matter at High Pressure (MALTA) Consolider Team, Universidad de Valencia, Edificio de Investigación, C/Dr Moliner 50, Burjassot, 46100, Valencia, Spain.
The production of hydrogen (H) fuel through electrocatalysis is emerging as a sustainable alternative to conventional and environmentally harmful energy sources. However, the discovery of cost-effective and efficient materials for this purpose remains a significant challenge. In this study, we explore the potential of the transition-metal-substituted YNS MXene as a promising candidate for hydrogen production through the hydrogen evolution reaction (HER).
View Article and Find Full Text PDFNanomaterials (Basel)
December 2024
State Key Laboratory of Chemical Safety, College of Control Science and Engineering, China University of Petroleum (East China), Qingdao 266580, China.
With the growing severity of air pollution, monitoring harmful gases that pose risks to both human health and the ecological environment has become a focal point of research. Titanium dioxide (TiO) demonstrates significant potential for application in SO gas detection. However, the performance of pure TiO is limited.
View Article and Find Full Text PDFSubst Use Misuse
January 2025
Department of Psychological and Brain Sciences, Texas A&M University, College Station, Texas, USA.
Persons with posttraumatic stress disorder (PTSD) compared to those without evince high rates of hazardous drinking, or patterns of alcohol consumption that increase the risk for harmful consequences. One potential marker of vulnerability for PTSD-hazardous drinking comorbidity may be smoking behavior. Individuals with PTSD have a higher prevalence of smoking and smoke at higher rates.
View Article and Find Full Text PDFBr J Clin Pharmacol
January 2025
Parexel International, Durham, North Carolina, USA.
Early approval mechanisms, such as conditional approval in the EU, have been used extensively to provide timely access to therapeutic innovations to cancer patients with unmet medical needs. While based on promising early evidence, such approvals are challenging from many perspectives due to the lack of comprehensive data. The limitation typically relates to data that demonstrates clinical benefit via early endpoints and is only acceptable when the early evidence is particularly convincing to assume that the benefits of early access are greater than the potential harms.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!